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Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only known curative therapy for
chronic myeloid leukemia (CML); however, it is rarely utilized given the excellent long-term results with
tyrosine kinase inhibitor (TKI) treatment. The purpose of this study is to examine HSCT outcomes for patients
with CML who failed TKI therapy or presented in advanced phase and to identify predictors of survival,
relapse, and nonrelapse mortality (NRM). Fifty-one patients with CML underwent HSCT for advanced disease
at diagnosis (n ¼ 15), TKI resistance as deﬁned by the European LeukemiaNet guidelines (n ¼ 30), TKI
intolerance (n ¼ 2), or physician preference (n ¼ 4). At a median follow-up of 71.9 months, the 8-year overall
survival (OS), event-free survival (EFS), relapse, and NRM were 68%, 46%, 41%, and 23%, respectively. In
univariate analysis, predictors of OS included ﬁrst chronic phase (CP1) disease status at HSCT (P ¼ .0005),
European Society for Blood and Marrow Transplantation score 1 to 4 (P ¼ .04), and complete molecular
response (CMR) to HSCT (P < .0001). Donor (female) to patient (male) gender combination (P ¼ .02) and CMR
to HSCT (P < .0001) predicted lower relapse. In multivariate analysis, CMR to HSCT remained an independent
predictor of OS (odds ratio [OR], 43), EFS (OR, 56) and relapse (OR, 29). This report indicates that the outlook is
excellent for those patients who remain in CP1 at the time of HSCT and achieve a CMR after HSCT. However,
only approximately 50% of those in advanced phase at HSCT are long-term survivors. This highlights the
ongoing need to try to identify patients earlier, before disease progression, who are destined to fail this
treatment to optimize transplantation outcomes.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative
neoplasm characterized by marrow hyperplasia associated
with a speciﬁc cytogenetic abnormality, known as the Phil-
adelphia chromosome (Ph), consisting of the reciprocal
translocation between chromosomes 9 and 22. This results in
the fusion of the Abelson (ABL) oncogene on chromosome 9
to the breakpoint cluster region (BCR) gene on chromosome
22 creating a fusion gene (BCR-ABL). This encodes for adgments on page 1443.
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ty for Blood and Marrow Transplantation.tyrosine kinase and is instrumental in the phosphorylation of
other proteins, resulting in a leukemic phenotype.
Historically, treatment for CML included either interferon
alpha (IFN) or, alternatively, allogeneic hematopoietic stem
cell transplantation (HSCT) for those patients considered
appropriate candidates and where a suitable matched donor
was available. However, with the introduction of the tyrosine
kinase inhibitor (TKI) imatinib mesylate (IM), therapy for
CML changed dramatically. The landmark international ran-
domized trial between IFN and IM (International Random-
ized Study of Interferon versus STI571 [IRIS]) for patients
with newly diagnosed CML in chronic phase (CP) showed a
cumulative best complete cytogenetic response (CCR) of 82%
with the corresponding overall survival (OS) and freedom
from progression at 6 years of 88% and 93%, respectively [1].
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patients; however, approximately 15% to 25% of patients
treated with IM will develop resistance or intolerance,
necessitating a change in therapy. More recently, the second-
generation TKIs dasatinib, nilotinib, and bosutinib have been
introduced for the treatment of patients with IM resistance
and/or intolerance, with reported response rates that
approximate 50% [2-4]. The second-generation TKIs have
also been studied for the treatment of newly diagnosed pa-
tients with CML, where faster and deeper molecular
responses and lower progression rates have been observed in
comparison to IM [5-7].
Given the excellent long-term results with TKI treatment
for the majority of patients with CML in CP, allogeneic HSCT
is now rarely utilized. Indeed, the indications for HSCT are
now generally limited to patients with TKI resistance or
intolerance or for patients with advanced phases of disease
where TKI therapy is not considered durable [8]. Although
studies have shown that prior treatment with TKIs does not
appear to increase immediate transplantation-related
morbidity or mortality [9], fewer reports are available de-
tailing the long-term HSCT outcomes for this patient popu-
lation. In particular, whether overall survival (OS),
progression-free survival (PFS), and relapse for patients
with CML undergoing allogeneic HSCT in the TKI era have
been altered by an initial therapeutic approach with IM
remain less well studied. Therefore, the purpose of this
report is to examine the clinical characteristics, HSCT out-
comes, and long-term follow-up of patients diagnosed with
CML in CP who fail initial TKI treatment and to identify
predictors of post-HSCT survival, relapse, and nonrelapse
mortality (NRM). In addition, patients presenting with
advanced disease at diagnosis (accelerated phase [AP] and
blast phase [BP]) and who received initial treatment with
TKIs as a bridge to HSCT were also studied to further evaluate
HSCT outcomes in this patient population.PATIENTS AND METHODS
From January 1, 2002 to April 30, 2013, 55 consecutive patients
diagnosed with CML underwent allogeneic HSCT at our institution. This
represents 7% of all allogeneic HSCTs performed during this time interval.
Indications for transplantation included resistance to TKI therapy as deﬁned
by the European LeukemiaNet (ELN) guidelines [8] in 30 patients, intoler-
ance to TKI therapy in 2 patients, advanced disease (AP or BP) at diagnosis in
15 patients, and physician or patient preference in 4 patients. An additional
4 patients had not received TKI treatment during this time period and were
excluded from further analysis. Therefore, 51 patients were reviewed and
are the subject of this report.Pretransplantation Therapy and Monitoring
All patients underwent a bone marrow (BM) aspirate and biopsy with
cytogenetic analysis at diagnosis. Patients with CML CP received IM as
initial therapy, except for 5 patients who were treated with IFN before
commencing IM when it became commercially available. Second gener-
ation TKIs (dasatinib and nilotinib) were only utilized for patients with
documented resistance or intolerance to IM therapy. Patients were fol-
lowed according to ELN treatment guidelines [8], including a complete
blood count at least once per month and cytogenetic analysis from BM
specimens every 3 to 6 months thereafter. Starting in 2004, quantitative
reverse transcriptase polymerase chain reaction (QPCR) of BCR-ABL
transcripts on peripheral blood (PB) specimens was performed every 3
months starting from diagnosis and was reported as log reductions, as
determined by comparison of the measured value to the log value
obtained at diagnosis or an averaged baseline value (þ.1), as adapted by
Hughes and Branford [10]. Once QPCR monitoring became readily avail-
able and molecular equivalents to cytogenetic responses were estab-
lished, routine BM tests with cytogenetic analysis were no longer
performed for monitoring purposes, provided the response to therapy
was satisfactory according to the ELN treatment guidelines. For patients
who did not achieve the treatment milestones per the ELN guidelines, orwho later developed progression (resistance) after an initial response, a
BM aspirate and biopsy with a full karyotype was performed to establish
current disease status and to determine whether progression to AP or BP
was present. Before the availability of the second-generation TKIs,
transplantation-eligible patients with IM resistance or intolerance were
offered allogeneic HSCT if a suitable donor was available. Second-
generation TKIs became available at our institution on November 1,
2007, and after this time, patients with IM resistance or intolerance were
generally offered a trial of treatment with these newer agents if still in CP,
and HSCT was reserved for those patients with an unsatisfactory thera-
peutic response or if progression to AP or BP had occurred.
For those patients presenting with CML in advanced phase (AP or BP)
who were deemed transplantation eligible, treatment with IM therapy with
orwithout concomitant conventional chemotherapy as a bridge toHSCTwas
undertaken in an attempt to achieve CP status while awaiting donor
conﬁrmation.
From 2006 onwards, mutational analysis by bidirectional sequencing of
the ABL kinase domain of the BCR-ABL fusion transcript using a nested
RT-PCR technique was also undertaken for those patients developing
resistance or with an unsatisfactory treatment response.
Conditioning Regimens and Stem Cell Source
Details of the conditioning regimens and stem cell source are shown in
Table 1. All chemotherapy doses were based on the lesser of the corrected
body weight (.5 kg [ideal body weight þ actual body weight]) or the actual
body weight. The preparative regimen utilized was dependent on disease
status at transplantation, the donor type (related or unrelated), patient age,
and comorbidities. All transplantations were myeloablative (total body
irradiation [TBI] 1200 cGy and i.v. cyclophosphamide 150 mg/kg or i.v.
busulfan 12.8 mg/kg and i.v. cyclophosphamide 120 mg/kg), with the
exception of 3 patients who received reduced-intensity conditioning regi-
mens (i.v. ﬂudarabine 150 mg/m2, i.v. busulfan 6.4 mg/kg, and i.v. alemtu-
zumab 100 mg [n ¼ 2] or ﬂudarabine 90 mg/m2 and TBI 200 cGy [n ¼ 1]).
The stem cell source varied over the time period of the study. Eight
patients received BM and 43 patients received PB from an HLA-matched
sibling or an unrelated donor. HLA matching for unrelated donors was
based onmolecular typing for HLA-A, -B, -C, and -DRB1. Standard supportive
care techniques and graft-versus-host disease (GVHD) prophylaxis were
employed as previously described [11].
Post-Transplantation Therapy and Monitoring
The standard monitoring practice after transplantation included a BM
analysis with standard karyotyping and XY FISH for gender-mismatched
transplantations 100 days after transplantation. For reduced-intensity
transplantations, patient and donor lymphoid and myeloid chimerism
were also performed on fractionated PB specimens from day 60 and day 100
after transplantation, utilizing microsatellite analysis of genomic DNA by
comparison of the averaged ampliﬁcation of donor and recipient alleles of
informative microsatellite markers, as determined from pretransplantation
specimens. In addition, institutional guidelines recommended molecular
analysis of BCR-ABL on PB on a 3-monthly basis for the ﬁrst 2 years, then
every 6 months if complete molecular remission (CMR) was achieved. In the
event of molecular relapse, a BM analysis and karyotype were performed,
and molecular analysis continued every 3 months or more frequently at
physician discretion. Therapeutic intervention was typically undertaken
based on cytogenetic or hematologic relapse or for increasing molecular
BCR-ABL transcripts in the event of molecular relapse only. TKI therapy or
any other chemotherapy was not given as a maintenance treatment after
HSCT in an attempt to decrease the risk of relapse.
Deﬁnitions
CML CP was deﬁned as <10% blasts and <20% basophils in PB or BM
without extramedullary disease. CML AP was deﬁned as 10% to 20% blasts,
>20% basophils, platelet count < 100  109/L unrelated to therapy, or
cytogenetic clonal evolution. CML BPwas deﬁned by>20% blasts in PB or BM
or extramedullary leukemic involvement. Complete hematologic response
(CHR) was deﬁned as normalization of PB count and absence of all signs and
symptoms of disease. Cytogenetic responses were classiﬁed as complete if
therewere no Phþmetaphase cells in BM or a 2-log reduction in PB BCR-ABL
transcripts compared with baseline,minor (35% to 95% Phþmetaphases), or
major (1% to 34% Phþ metaphases), or a 1-log reduction in PB BCR-ABL
transcripts compared with baseline (MCR). Hematologic relapse was
deﬁned by the reappearance of a leukocytosis in PB or BMwith an abnormal
differential typical of CML with conﬁrmation by cytogenetic analysis. Cy-
togenetic relapse involved the reappearance of 1 or more Phþ metaphases
on cytogenetic analysis. Major molecular response (MMR) was deﬁned as a
3-log reduction in PB BCR-ABL transcripts compared with baseline. The
threshold for CMR was based on the level below which BCR-ABL transcripts
Table 1
Clinical Characteristics
Characteristic Total
(N ¼ 51)
TKI Failure
(n ¼ 32)
Age at HSCT, median (range), yr 45 (22-63) 45 (22-61)
Sex
Male 34 21
Female 17 11
Disease phase at diagnosis
CP 33 30
AP 08 02
BP 10 0
Disease phase at HSCT
CP1 17 14
Advanced phase 34 18
Sokal score
Low 11 08
Intermediate 11 10
High 28 13
Not available 01 01
Therapy before HSCT
Imatinib alone 22 09
Imatinib þ another TKI 10 10
Imatinib þ chemotherapy 
another TKI
19 13
Best response to imatinib
CHR 21 17
MCR 19 11
CCR 11 04
Cytogenetic status at HSCT
Minor or no response 19 17
MCR 16 08
CCR 14 07
Failed 02 0
Time from diagnosis to HSCT,
median (range), mo
10.2 (1.9-144.7) 16.4 (5.7-144.7)
Time from start of IM to HSCT,
median (range), mo
9.1 (1.2-142.6) 16 (3.4-142.6)
EBMT score
1-4 33 21
>4 18 11
Donor type
Related 24 12
Unrelated 27 20
Donor to recipient gender
combination
Female to male 11 05
Female to female 06 04
Others 34 23
Source of stem cells
BM 08 04
PB 43 28
Conditioning regimen
BuCy 23 13
CyTBI 25 17
RIC 03 02
PBSC indicates peripheral blood stem cell; BuCy, busulfan þ cyclophos-
phamide; CyTBI, cyclophosphamide þ total body irradiation; RIC, reduced-
intensity conditioning.
Data presented are n, unless otherwise indicated.
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Molecular relapse was deﬁned as reversion to a positive RT-PCR or quanti-
tative PCR, repeated on 2 separate occasions at least 1 month apart.
Neutrophil engraftmentwas deﬁned as the ﬁrst of 3 consecutive days with an
absolute neutrophil count > .5 109/L, and platelet engraftmentwas deﬁned
as the ﬁrst of 3 consecutive days with a platelet count > 20  109/L without
transfusion support. Acute GVHD (aGVHD) and chronic GVHD (cGVHD) were
graded according to clinical consensus criteria [12,13].Statistical Analysis
The probabilities of survival were calculated using the methods of
Kaplan and Meier and compared using the log-rank test [14]. The time from
HSCT to the date of death or last contact was used to calculate OS. The time
from HSCT to the date of death, relapse, or last contact was used to calculate
event-free survival (EFS). Incidences of grades 2 to 4 aGVHD, cGVHD, NRM,and relapse were calculated using the competing risks methodology
described by Klein et al. [15]. Conﬁdence intervals (CI) for cumulative in-
cidences were computed using the method proposed by Choudhury [16].
To examine potential factors inﬂuencing OS, EFS, relapse, and NRM, the
following prognostic variables were analyzed: age at HSCT (<35 years
versus 35 years), patient gender, interval from diagnosis to HSCT (<1 year
versus  1 year), year of HSCT (2002 to 2006 versus 2007 to 2013), Sokal
score at diagnosis (low/intermediate risk versus high risk), disease status at
diagnosis (CP versus AP/BP), disease status at HSCT (CP1 versus advanced
phase), best response to IM therapy before HSCT (CHR versus MCR versus
CCR), therapy before HSCT (IM alone versus IM þ chemotherapy  another
TKI versus IM þ another TKI), cytogenetic status at HSCT (no response or
minor response versus MCR or better), European Society for Blood and
Marrow Transplantation (EBMT) score (1 to 4 versus >4), conditioning
regimen (busulfan and cyclophoshomide versus cyclophosphamide and
TBI), donor type (related versus unrelated), donor to patient gender com-
bination (female to male versus female to female versus other), status of
aGVHD (grades 0 and 1 versus grades 2 to 4), and best molecular response to
HSCT (CMR versus no CMR). Univariate analysis of categorical variables and
interval variables was performed using chi-square tests and t-tests,
respectively. Multivariate analysis was performed using a Cox regression
model to evaluate the potential association of those factors with OS, EFS,
relapse, and NRM [17]. Variables were included in themultivariate analysis if
they had a P value< .10 in the univariate analysis. Factors were considered to
be statistically signiﬁcant if they had an associated P value< .05. All P values
are two sided. The univariate analysis was performed on thewhole cohort of
51 patients and repeated separately on the cohort of 32 patients with TKI
resistance or intolerance. Multivariate analysis was performed on the whole
cohort (n ¼ 51) only. The effect of cGVHD on OS and EFS was analyzed using
extended Cox regression modeling with time-dependent covariates. The
effect of cGVHD on relapse and NRM was evaluated using the proportional
subdistribution hazards model for relapse and NRM, where the model
included cGVHD as a binary time-dependent covariate with competing risks
analysis. The model was ﬁtted to the data supplied by all patients and the
patients with TKI failure, respectively, using multiple imputation in
conjunction with Cox regression as implemented in the R package kmi [18].RESULTS
Patient Characteristics
Fifty-one patients were treated with IM from January 1,
2002 through April 30, 2013 and underwent HSCT. Patient
characteristics are detailed in Table 1. There were 34 males
and 17 females. The median age at HSCT was 45 years (range,
22 to 63) and the median time from diagnosis to HSCT was
10.2 months (range, 1.9 to 144.7). Sokal score was high risk in
28 patients (55%). The indication for HSCT included IM
resistance in 30 patients, IM intolerance in 2 patients,
advanced disease at diagnosis in 15 patients, and physician
or patient preference in 4 patients. At diagnosis, the majority
of patients were in CP1 (n ¼ 33); however, only 17 patients
remained in CP1 at the time of HSCT, with 16 of the 33 pa-
tients diagnosed in CP1 progressing to a more advanced
disease status after IM treatment. Therefore, at the time of
HSCT, 41 patients were in CP (CP1 [n ¼ 17], CP2 [n ¼ 21], CP3
[n ¼ 3]), 9 were in AP, and only 1 patient remained in BP. Of
the 15 patients who presented in advanced phase (AP [n¼ 5],
BP [n¼ 10]), all the AP patients and 4 BP patients received IM
therapy alone before HSCT; the other 6 patients presenting in
BP received a combination of IM and systemic chemotherapy
before proceeding to HSCT. Best response to this therapy at
the time of HSCT was CHR (n¼ 3), MCR (n¼ 7), and CCR (n¼
5). For the subgroup of 32 patients with IM failure (resistance
or intolerance), all except 2 patients were in CP1 at the time
of diagnosis; the other 2 patients were in AP. However, the
intention was to treat with IM as primary therapy and
reserve HSCT for an inadequate response to TKI treatment.
One of these AP patients transformed to BP and achieved a
CP2 with a CCR after receiving dasatinib therapy. The other
AP patient remained in AP at the time of HSCT and did not
receive additional therapy after IM failure. The 2 patients
with IM intolerance proceeded directly to HSCT before the
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at HSCT and the best response to IM therapy was CHR and
MCR. The remaining 28 patients with IM failure were all in
CP1 at diagnosis, but 13 progressed to BP and 3 progressed to
AP on IM therapy. The 3 AP patients did not receive salvage
therapy after IM failure and proceeded to HSCT directly. For
the other 13 patients, salvage therapy included dasatinib
alone (n ¼ 1), systemic chemotherapy with a second-
generation TKI (n ¼ 7), and systemic chemotherapy alone
without additional TKIs (n ¼ 5). Two of the 7 patients failed
the salvage chemotherapy and TKI and received further
treatment with a third TKI before HSCT. Responses to this
therapy were CHR but no or minor cytogenetic response (n¼
4), MCR (n ¼ 4), and CCR (n ¼ 5). The other 12 patients with
IM resistance remained in CP1. Four of these 12 patients
received no further therapy before proceeding to HSCT; in 2
of theses cases, failure to IM occurred before availability of
second-generation TKIs. The third patient underwent HSCT
after IM failure with no cytogenetic response and the fourth
patient had lost MMR in association with a T315I mutation
but remained in CCR at the time of HSCT. The other 8 patients
in CP1 received second-generation TKIs (dasatinib [n ¼ 6],
nilotinib [n¼ 1], bosutinib [n¼ 1]). The cytogenetic response
to the salvage therapy for these 8 patients was a minor or no
cytogenetic response (n ¼ 5) and MCR (n ¼ 3). Lastly, 4 pa-
tients underwent a HLA-matched sibling HSCT for physician
or patient preference; 3 of these patients were in CP1 at
diagnosis and remained in CP1 at the time of HSCT. The cy-
togenetic response to IM therapy was no response, MCR, and
CCR. The fourth patient was in AP on the basis of clonal
evolution at diagnosis and remained in AP (clonal evolution)
with a CCR at HSCT.
The best cytogenetic response to IM and the pre-HSCT
cytogenetic status at the time of the most recent TKI
administered for all 51 patients is detailed in Table 1. Thirty of
the 51 patients (59%) had achieved a MCR or CCR to initial IM
therapy, which included concomitant chemotherapy for
those presenting in advanced phases of disease, and 30 pa-
tients (59%) were in a MCR or better at the time of HSCT.
Mutational analysis of the BCR-ABL kinase domain was un-
dertaken before HSCT in 23 of the 30 patients with IM
resistance; 4 of the 23 patients had mutations identiﬁed,
which consisted of a T315I mutation in 2 patients, a D276G
mutation in 1 patient, and both Y253H and V379I mutations
in the fourth patient.
The EBMT scores for the 51 patients are detailed in Table 1.
The EBMT score was >4 in 18 patients (35%). All patients
received grafts from HLA-matched sibling donors (n ¼ 24) or
HLA-matched unrelated donors (n ¼ 27). The unrelated do-
nors were fully matched at the HLA-A, -B, -C, and -DRB1 loci
(n ¼ 18) or had 1 antigen (n ¼ 5) or 2 antigen (n ¼ 4) mis-
matches. The conditioning regimen was myeloablative in 48
patients; 3 patients had reduced-intensity conditioning
because of advanced age.
Engraftment and GVHD
The minimum total nucleated cell dose was 2  108/kg
recipient body weight. All patients achieved primary
engraftment. The median times to neutrophil and platelet
recovery were 17 days (range, 8 to 30) and 14 days (range, 8
to 278), respectively. Platelet engraftment was not achieved
in 2 patients before their death from cGVHD and relapse, 8.8
and 17.3 months after HSCT, respectively. Thirty-six patients
developed aGVHD that was grades 2 to 4 in 28 patients. The
cumulative incidence of grades 2 to 4 aGVHD at 100 days was55% (95% CI, 40% to 67%) and 1 patient died of aGVHD, 51
days after HSCT. Of the 51 patients, 38 developed cGVHD,
which was extensive in 26 patients. The 4-year cumulative
incidence of cGVHD (limited and extensive) was 79% (95% CI,
64% to 88%) and resulted in 4 deaths at 8.8, 9.1, 50.3, and 56.9
months after HSCT.
NRM
Eight of the 51 patients died of complications after HSCT
unrelated to disease relapse, including aGVHD (n ¼ 1),
cGVHD (n ¼ 4), infection (n ¼ 1), respiratory failure (n ¼ 1),
and cerebral hemorrhage (n ¼ 1). Two of the 4 patients who
succumbed to cGVHD also had a concomitant bacterial or
fungal infection. All 8 of the patients were in advanced
phases of disease at the time of HSCT (AP [n¼ 2], CP2 [n¼ 3],
CP3 [n ¼ 3]) with an EBMT score  5 in 6 patients and an
EBMT score 4 in the other 2 patients. The cumulative in-
cidences of NRM at 1 year and 5 years for all 51 patients were
10% (95% CI, 4% to 20%) and 20% (95% CI, 9% to 34%),
respectively. The corresponding NRM at 1 year and 5 years
for the patients who underwent transplantation for TKI
failure were 6% (95% CI, 1% to 19%) and 14% (95% CI, 3% to
34%), respectively. In univariate analysis of all 51 patients
undergoing HSCT, CP1 disease status at HSCT (P ¼ .008),
EBMT score 1 to 4 (P ¼ .004), and a CMR to HSCT (P < .0001)
were associated with a lower NRM (Table 2). In univariate
analysis of the TKI failure subgroup, CP1 disease status at
HSCT (P ¼ .05) and a CMR to HSCT (P ¼ .02) were associated
with a lower NRM (Table 3). The multivariate analysis was
not viable because of the small number of events.
Relapse
Eighteen of the 51 patients relapsed at a median of 12
months (range, 2.5 to 101) from the date of HSCT. The re-
lapses were hematologic (n ¼ 10), cytogenetic (n ¼ 1), and
molecular (n ¼ 7). Of the 18 patients, 6 were in CP1 at the
time of HSCT and 12 had advanced disease. The cumulative
incidences of relapse at 1 year and 5 years after HSCT for all
51 patients were 18% (95% CI, 9% to 29%) and 37% (95% CI, 23%
to 51%), respectively. For the 32 patients who underwent
transplantation for TKI failure, the cumulative incidences of
relapse at 1 year and 5 years after HSCT were 22% (95% CI, 9%
to 38%) and 37% (95% CI, 19% to 54%), respectively. In uni-
variate analysis of all 51 patients, a female donor to a male
recipient combination (P¼ .02) and the attainment of CMR to
HSCT (P< .0001) were associated with a lower risk of relapse
(Table 2). For the 48 patients who survived to day 100, the
subdistribution hazard ratio of cGVHD versus no cGVHDwith
respect to relapse was .79 (95% CI, .24 to 2.6; P ¼ .70). In
univariate analysis of the TKI failure subgroup, female donor
to male recipient combination (P ¼ .04), attainment of CMR
to HSCT (P < .0001), and treatment with TKI alone before
HSCT (P ¼ .04) were associated with a lower risk of relapse
(Table 3). For the 31 patients with TKI failure who survived to
day 100, the subdistribution hazard ratio of cGVHD versus no
cGVHDwith the respect to relapse was .84 (95% CI, .21 to 3.4;
P ¼ .81). In multivariate analysis, the attainment of CMR to
HSCT (odds ratio [OR], 29.4; P < .001) remained highly
associated with a lower probability of relapse. A female
donor tomale recipient (OR, 6.0; P¼ .08) also showed a trend
to a lower probability of relapse.
Postrelapse Therapy
Eight of the 18 patients relapsed in BP and received
therapy with IM (n ¼ 2), dasatinib (n ¼ 2), dasatinib with or
Table 2
Univariate Analysis of Variables Affecting Transplantation Outcomes
Variable (N ¼ 51) OS (%) P Value EFS (%) P Value REL (%) P Value NRM (%) P Value
Disease status at HSCT <.001 .01 .23 .008
CP1 100 64 36 0
Advanced 48 34 42 41
Donor type .62 .05 .21 .09
Related 72 58 33 14
Unrelated 65 34 50 32
Donor to patient gender combination .30 .05 .02 .96
Female to male 81 67 17 19
Female to female 75 75 0 25
Others 63 33 57 22
EBMT score .04 .04 .61 .004
1-4 78 57 39 7
>4 50 25 44 56
Best response to HSCT <.0001 <.0001 <.0001 <.0001
CMR 92 67 25 11
No CMR 17 0 88 100
REL indicates relapse.
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chemotherapy (n ¼ 3), and ponatinib (n ¼ 1). Two of 8 pa-
tients relapsing in BP achieved a complete remission and
remain in CMR 87.6 and 82.6 months from the date of
relapse. The relapse therapy in those 2 patients was dasatinib
alone in 1 patient and dasatinib with concomitant acute
lymphoid leukemiaetype induction chemotherapy in the
second patient. The other 6 patients who relapsed in BP died
of disease a median of 7.3 months from the date of relapse.
There were 10 other relapses, including 2 patients who
relapsed in CP, 1 of whom received dasatinib and donor
lymphocyte infusion (DLI) and remains alive in MMR 38.5
months from the date of relapse. The other patient was
initially treated with IM followed by a second HSCT, which
resulted in graft failure. The patient underwent a third HSCT
and died of relapsed disease 88.7 months from the date of
the ﬁrst relapse. One other patient experienced a cytogenetic
relapse 14.9 months from the date of HSCT and received
nilotinib and DLI and remains alive in CMR 39.8 months from
the date of relapse. The ﬁnal 7 patients had molecular re-
lapses, 6 of whom received treatment with IM (n¼ 1), IM and
DLI (n ¼ 1), dasatinib (n ¼ 2), DLI (n ¼ 1), and withdrawl of
immunosuppression (n ¼ 1). These 6 patients achieved a
CMR with these therapies and remain alive at 60.1, 23.5, 5,
42, 48.4, and 70.3 months from the date of relapse. The
seventh patient was treated initially with IM and thenTable 3
Univariate Analysis of Variables Affecting Transplantation Outcomes for Patients w
Variable (n ¼ 32) OS (%) P Value EFS (%)
Disease status at HSCT .006
CP1 100 70
Advanced 53 35
Donor to patient gender combination .43
Female to male 100 100
Female to female 50 50
Others 73 39
Best response to imatinib before HSCT .02
CHR 51 37
MCR 100 72
CCR 100 38
Best response to HSCT <.0001
CMR 93 72
No CMR 29 0
Therapy before HSCT .15
Imatinib alone 89 67
Imatinib þ chemo  TKI 61 38
Imatinib þ another TKI 75 60dasatinib, but the patient died very quickly with disease
progression to BP 1 month after the date of relapse.
Survival
Thirty-ﬁve of the 51 patients remain alive with a median
follow-up of 71.9 months (range, 12.9 to 139.9) for survivors.
Of these 35 patients, 25 had undergone HSCT for TKI failure,
6 for advanced disease at diagnosis, and 4 for physician
preference. The 8-year OS and EFS for all 51 patients were
68% (95% CI, 52% to 80%) and 46% (95% CI, 30% to 60%),
respectively (Figure 1). For those 32 patients who underwent
transplantation for TKI failure, the 8-year OS and EFS were
75% (95% CI, 54% to 88%) and 52% (95% CI, 31% to 69%),
respectively (Figure 2). In univariate analysis of all 51 pa-
tients, CP1 disease status at HSCT (P ¼ .0005), EBMT score 1
to 4 (P ¼ .04), and attainment of CMR to HSCT (P < .0001)
were predictive of OS (Table 2). Similarly, CP1 status at HSCT
(P ¼ .006), a cytogenetic response (MCR or CCR) to IM ther-
apy before HSCT (P ¼ .02), and attainment of CMR after HSCT
(P < .0001) were also predictive of improved OS for the 32
patients who underwent HSCT for TKI failure (Table 3). With
regards to EFS, in univariate analysis of all 51 patients, CP1
status at HSCT (P ¼ .01), EBMT score 1 to 4 (P¼ .04), and CMR
after HSCT (P < .0001) were predictive of improved EFS
(Table 2). When the TKI failure patients were examined
separately, CP1 status at HSCT (P ¼ .03) and CMR after HSCTith TKI Failure
P Value REL (%) P Value NRM (%) P Value
.03 .14 .05
30 0
45 36
.05 .04 .50
0 0
0 50
57 10
.38 .71 .17
44 35
28 0
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21 9
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25 11
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20 25
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Figure 1. Overall survival and event-free survival from allogeneic HSCT for all
patients.
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analysis of all 51 patients, the attainment of CMR after HSCT
remained signiﬁcantly associated with OS (OR, 42.9; P <
.001) and EFS (OR, 56.6; P < .001).DISCUSSION
Given the remarkable efﬁcacy of TKI therapy for CML,
the current recommendation of the ELN reserves HSCT for
those patients failing TKI therapy or who have advanced
phase disease where TKI therapy has demonstrated lower
efﬁcacy and durability [8]. Given this major shift over the
last 10 to 15 years in the timing of transplantations for
CML, the patient demographics have also changed for the
transplantation population. There are now a greater pro-
portion of patients in advanced phase at HSCT, with a
potentially longer period from diagnosis to HSCT and an
increased number of prior therapies (multiple TKIs). In the
pre-TKI era, the major factor inﬂuencing transplantation
outcome was disease phase at HSCT, with patients in
advanced phase faring poorly with OS of 10% to 30% [19].
Other predictors included patient age, donor type, donor/
recipient sex combination, and time from diagnosis to
HSCT as described in the EBMT score [20]. However, most
of this information was derived and validated from studies
in the pre-TKI era. How this may have been altered with
the introduction of TKI therapy for CML continues to be
evaluated and formed the subject of this report.
Our study conﬁrms the increasing proportion of advanced
phase patients undergoing HSCT and this has resulted in an
inferior EFS and OS for this patient subgroup. Indeed, those
patients in CP1 at the time of HSCT enjoyed a 100% OS at 8
years and 0% NRM. In contrast, the 8-year OS was 48% and
the NRM was 41% for the advanced phase patients. These
results are in keeping with the German CML IV study whereSu
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Figure 2. Overall survival and event-free survival from allogeneic HSCT for
patients with tyrosine kinase inhibitor (TKI) failure.they reported a 3-year OS rate of 91% for CP patients and only
59% for patients in advanced phase at HSCT [21]. Similar
results were also reported in a study by Oyekunle et al.,
where 68 patients with CML underwent HSCT, 48 of whom
had prior TKI therapy. Those patients in CP1 had an OS of
85%; however, the OS was only 43% for advanced phase pa-
tients [22].
There has been some controversy as to whether previous
TKI therapy increases the risk of relapse after HSCT. Partic-
ularly for those patients receiving multiple lines of TKIs for
resistance or intolerance, this could lead to a delay in HSCT
with, potentially, a greater proportion of patients harboring
mutated clones with or without disease progression in the
interval. A report from MD Anderson conﬁrms that patients
with BCR-ABL mutations developing after TKI failure are
more likely to develop advanced diseasewith a less favorable
outcome with HSCT (2-year OS of 44%) compared with
patients without the mutation (2-year OS of 76%) [23]. Un-
fortunately, we only had 4 patients in our study who had
BCR-ABL mutations identiﬁed before HSCT. Therefore, it was
not possible to examine the impact of mutational status on
HSCT outcome in our study, but it is worth noting that 2 of
the 4 patients had progressed to BP at the time the mutation
was detected, supporting the association of mutations with
the development of advanced disease.
The administration of TKI therapy before HSCT may also
inﬂuence transplantation outcome and the risk of relapse by
modulating cGVHD. IM therapy is thought to have immu-
nomodulatory effects with a decrease in the incidence of
cGVHD after HSCT [24]. In a report by Deininger et al., prior
IM treatment was associated with a reduction in the inci-
dence of cGVHD with a trend to an increased risk of relapse
compared with a historical control population [25]. In our
study, all patients had received prior IM therapy so it was,
therefore, not possible to evaluate the role of IM itself in
transplantation outcomes. However, we did note a higher
risk of relapse among the 32 patients with TKI failure who
received chemotherapy after failing IM treatment compared
with IM treatment alone. The risk of relapse, however, did
not appear signiﬁcantly increased for patients receiving 2 or
more TKIs without chemotherapy. Therefore, the increased
risk of relapse in the TKI plus chemotherapy cohort is likely a
reﬂection of the disease status at HSCT, whereby all the pa-
tients receiving chemotherapy in addition to IM had
advanced phase disease, compared with only 4 of 19 patients
in the IM alone or IM plus additional TKIs. Thus, it is
encouraging that treatment with multiple TKIs does not
appear to increase the risk of relapse after HSCT compared
with IM alone, provided patients have not progressed to a
more advanced phase of disease.
With regards to the role of cGVHD and the risk of relapse,
we found a trend towards a lower risk of relapse for those
patients developing cGVHD. However, this did not reach
statistical signiﬁcance. This is perhaps related to the small
number of patients in our study and limited statistical power
or, alternatively, this could also be a reﬂection of the rela-
tively high number of patients with advanced phase disease
at HSCT where the effects of cGVHD on preventing relapse
maybe lower than in CP1. This is supported by the inferior
results of DLIs in advanced phase relapses as well as the
higher relapse rates seen with reduced-intensity trans-
plantations in the setting of advanced disease, where a graft-
versus-leukemia (GVL) effect is important for disease control
[26-28]. However, we did ﬁnd that the donor/recipient sex
combination was predictive of HSCT outcome, with a lower
A.P. Nair et al. / Biol Blood Marrow Transplant 21 (2015) 1437e1444 1443rate of relapse with female donors. It is well recognized that
female donors can result in a higher risk of cGVHD in the
recipient [29] and, thus, the lower relapse rate is felt to
represent the GVL effect associated with cGVHD. It is possible
that the GVL effect associated with female donors was pre-
sent in the absence of overt clinical cGVHD to explain the
seemingly lack of clear association of clinical cGVHD on
relapse rates in our study. It is also important to recognize
that cGVHD, while effective in reducing relapse at least in
CP1, can be associated with increased morbidity after HSCT,
such that the potential beneﬁts of HSCT must be weighed
against pursuing non-HSCT therapies (second- or third-
generation TKIs) for individual patients.
In our study, the strongest predictor of transplantation
outcome was the achievement of a CMR after HSCT before
the administration of any additional salvage therapy for
persistent or recurrent disease. This was evidenced by the
fact that only 2 of the 16 patients not reaching a CMR after
transplantation are alive, with the other 14 patients dying
of disease progression or NRM, for an 8-year OS of 17%. On
the contrary, the patients achieving CMR enjoyed a 92% 8-
year OS. This observation is in keeping with the recent
study from Lee et al. that showed a 4.5-log reduction in
BCR-ABL transcripts (equivalent to our CMR threshold) 3
months after HSCT was associated with improved EFS [30].
Furthermore, in an earlier report from our group, the
attainment of CMR after HSCT was critical to long-term
survival in the setting of post-transplantation relapse
[31]. Together, these data would suggest that for the
TKI-resistant or advanced phase CML population after
HSCT, a marked reduction in disease burden is necessary
for sustained disease control. This is in contrast to the CML
population who didn’t undergo transplantation, where TKI
therapy resulting in a 2-log (equivalent to CCR) or a 3-log
reduction in BCR-ABL transcripts can result in durable
long-term remissions [32]. The difference may be related
to a more aggressive clone in the transplantation popula-
tion requiring deeper responses for sustained control.
In conclusion, despite the relatively small number of pa-
tients examined and, thus, limited statistical power, our
report indicates that many of the predictive factors for HSCT
outcome identiﬁed in the pre-TKI era remain equally
important for CML patients who have failed TKI therapy. For
those patients who remain in CP1 at the time of HSCT and
achieve a CMR after HSCT, the outlook is excellent. However,
only approximately 50% of those in advanced phase at HSCT
are long-term survivors. This highlights the ongoing need to
develop better predictive models for CML patients receiving
TKI therapy, to hopefully identify patients earlierdbefore
disease progressiondwho are destined to fail this treatment,
and to optimize transplantation outcome.ACKNOWLEDGMENTS
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